Cargando…
ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study
BACKGROUND: ClinicalTrials.gov (CT.gov) is the most comprehensive internet-based register of different types of clinical studies. Expanded access is the use of unapproved drugs, biologics, or medical devices outside of clinical trials. One of the key problems in expanded access is the availability t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587192/ https://www.ncbi.nlm.nih.gov/pubmed/34709189 http://dx.doi.org/10.2196/26890 |
_version_ | 1784598090520461312 |
---|---|
author | Borysowski, Jan Górski, Andrzej |
author_facet | Borysowski, Jan Górski, Andrzej |
author_sort | Borysowski, Jan |
collection | PubMed |
description | BACKGROUND: ClinicalTrials.gov (CT.gov) is the most comprehensive internet-based register of different types of clinical studies. Expanded access is the use of unapproved drugs, biologics, or medical devices outside of clinical trials. One of the key problems in expanded access is the availability to both health care providers and patients of information about unapproved treatments. OBJECTIVE: We aimed to evaluate CT.gov as a potential source of information about expanded access programs. METHODS: We assessed the completeness of information in the records of 228 expanded access programs registered with CT.gov from February 2017 through May 2020. Moreover, we examined what percentage of published expanded access studies has been registered with CT.gov. Logistic regression (univariate and multivariate) and mediation analyses were used to identify the predictors of the absence of some information and a study’s nonregistration. RESULTS: We found that some important data were missing from the records of many programs. Information that was missing most often included a detailed study description, facility information, central contact person, and eligibility criteria (55.3%, 54.0%, 41.7%, and 17.5% of the programs, respectively). Multivariate analysis showed that information about central contact person was more likely to be missing from records of studies registered in 2017 (adjusted OR 21.93; 95% CI 4.42-172.29; P<.001). This finding was confirmed by mediation analysis (P=.02). Furthermore, 14% of the programs were registered retrospectively. We also showed that only 33 of 77 (42.9%) expanded access studies performed in the United States and published from 2014 through 2019 were registered with CT.gov. However, multivariate logistic regression analysis showed no significant association between any of the variables related to the studies and the odds of study nonregistration (P>.01). CONCLUSIONS: Currently, CT.gov is a quite fragmentary source of data on expanded access programs. This problem is important because CT.gov is the only publicly available primary source of information about specific programs. We suggest the actions that should be taken by different stakeholders to fully exploit this register as a source of information about expanded access. |
format | Online Article Text |
id | pubmed-8587192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-85871922021-12-07 ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study Borysowski, Jan Górski, Andrzej J Med Internet Res Original Paper BACKGROUND: ClinicalTrials.gov (CT.gov) is the most comprehensive internet-based register of different types of clinical studies. Expanded access is the use of unapproved drugs, biologics, or medical devices outside of clinical trials. One of the key problems in expanded access is the availability to both health care providers and patients of information about unapproved treatments. OBJECTIVE: We aimed to evaluate CT.gov as a potential source of information about expanded access programs. METHODS: We assessed the completeness of information in the records of 228 expanded access programs registered with CT.gov from February 2017 through May 2020. Moreover, we examined what percentage of published expanded access studies has been registered with CT.gov. Logistic regression (univariate and multivariate) and mediation analyses were used to identify the predictors of the absence of some information and a study’s nonregistration. RESULTS: We found that some important data were missing from the records of many programs. Information that was missing most often included a detailed study description, facility information, central contact person, and eligibility criteria (55.3%, 54.0%, 41.7%, and 17.5% of the programs, respectively). Multivariate analysis showed that information about central contact person was more likely to be missing from records of studies registered in 2017 (adjusted OR 21.93; 95% CI 4.42-172.29; P<.001). This finding was confirmed by mediation analysis (P=.02). Furthermore, 14% of the programs were registered retrospectively. We also showed that only 33 of 77 (42.9%) expanded access studies performed in the United States and published from 2014 through 2019 were registered with CT.gov. However, multivariate logistic regression analysis showed no significant association between any of the variables related to the studies and the odds of study nonregistration (P>.01). CONCLUSIONS: Currently, CT.gov is a quite fragmentary source of data on expanded access programs. This problem is important because CT.gov is the only publicly available primary source of information about specific programs. We suggest the actions that should be taken by different stakeholders to fully exploit this register as a source of information about expanded access. JMIR Publications 2021-10-28 /pmc/articles/PMC8587192/ /pubmed/34709189 http://dx.doi.org/10.2196/26890 Text en ©Jan Borysowski, Andrzej Górski. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 28.10.2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Borysowski, Jan Górski, Andrzej ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title | ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title_full | ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title_fullStr | ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title_full_unstemmed | ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title_short | ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study |
title_sort | clinicaltrials.gov as a source of information about expanded access programs: cohort study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587192/ https://www.ncbi.nlm.nih.gov/pubmed/34709189 http://dx.doi.org/10.2196/26890 |
work_keys_str_mv | AT borysowskijan clinicaltrialsgovasasourceofinformationaboutexpandedaccessprogramscohortstudy AT gorskiandrzej clinicaltrialsgovasasourceofinformationaboutexpandedaccessprogramscohortstudy |